Novogen (KZIA) Expected to Announce Earnings on Friday

Novogen (NASDAQ:KZIA) will likely be issuing its resultson Friday, September 4th. Analysts expect Novogen to post earnings of ($0.6055) per share and revenue of $0.4890 million for the quarter.

Novogen Trading Down 0.2%

Novogen stock opened at $12.61 on Thursday. Novogen has a 1-year low of $4.86 and a 1-year high of $17.40. The firm has a 50-day moving average of $13.38 and a 200-day moving average of $11.42.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on KZIA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. Lake Street Capital initiated coverage on Novogen in a report on Thursday, June 11th. They set a “buy” rating and a $32.00 target price on the stock. BTIG Research raised their target price on Novogen from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Canaccord Genuity Group assumed coverage on shares of Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price target for the company. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $27.33.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.